A recent report from the Massachusetts Health Policy Commission used publicly available drug pricing data in an attempt to identify proxies to highlight the differences between what health plan sponsors reimburse their pharmacy benefit managers (PBM) for a prescription versus
JC Scott, president and CEO of the PBMs’ national trade group, the Pharmaceutical Care Management Association, said in a statement: “We are currently reviewing the proposed rule. However, previous point-of-sale proposals in Medicare have not advanced because they would significantly increase Medicare spending.”
For America’s pharmacy benefit managers, PBMs, the core mission is to increase access to affordable prescription drugs for all Americans. While PBMs have a proven track record of reducing prescription drug costs, it’s clear that for too many Americans prescription
President Trump needs a win on health care, and prescription drug costs are in the crosshairs. He issued an executive order to eliminate drug rebates paid to Medicare Part D plans, claiming that this would save seniors billions of dollars. To ensure
PhRMA was one of AAN’s biggest donors the previous year, giving it $6.1 million, federal regulatory findings show
The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken
PBMs: Committed to Helping Patients The Critical Path Forward: Rx Policies to Reduce Patient Costs, Improve Access For America’s pharmacy benefit managers, PBMs, our core mission is to increase access to affordable prescription drugs for all Americans. But more can
JC Scott President & Chief Executive Officer Meet JC Dylan Ashley Manager, Conferences and Industry Relations Meet Dylan Mike Baldyga Director, Public Affairs Meet Mike Angela Banks Vice President, Policy Meet Angela Christy Beach Executive Assistant to the President &
©2024 PCMA. All Rights Reserved.
